1Cell.Ai Named Best Healthtech Startup 2026

Recognised for Innovation in Precision Oncology & Patient Impact

Read the Announcement
Request a Callback
  • Home
  • Solutions
  • Technology
  • Products

      Products

      Early-stage Treatment Selection

      OncoTarget®

      Targeted biomarker testing

      OncoHRD®

      HRD testing for PARP therapy

      OncoIndx 360® Endometrium

      Endometrial cancer profiling

      OncoPredikt® BRS

      Breast cancer recurrence risk asse..

      Advanced Precision Oncology

      OncoIndx® Multi-Modal

      Integrated DNA, RNA & Protein Pro..

      OncoIndx® Prime+

      Advanced comprehensive genomic..

      Monitoring & Response

      OncoMonitor® MRD

      Minimal residual disease monitoring

      OncoAlibrex®

      Treatment response monitoring

      Complementary Solutions

      OncoRisk®

      Hereditary cancer risk assessment

      IHC Biomarkers

      Comprehensive biomarker analys.

      DrG

      An AI-powered clinical workspace

  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

  • Home
  • Solutions
  • Technology
  • Products

      Products

      Early-stage Treatment Selection

      OncoTarget®

      Targeted biomarker testing

      OncoHRD®

      HRD testing for PARP therapy

      OncoIndx 360® Endometrium

      Endometrial cancer profiling

      OncoPredikt® BRS

      Breast cancer recurrence risk asse..

      Advanced Precision Oncology

      OncoIndx® Multi-Modal

      Integrated DNA, RNA & Protein Pro..

      OncoIndx® Prime+

      Advanced comprehensive genomic..

      Monitoring & Response

      OncoMonitor® MRD

      Minimal residual disease monitoring

      OncoAlibrex®

      Treatment response monitoring

      Complementary Solutions

      OncoRisk®

      Hereditary cancer risk assessment

      IHC Biomarkers

      Comprehensive biomarker analys.

      DrG

      An AI-powered clinical workspace

  • Resources

      Resources

      Publication

      Peer-reviewed research and manuscripts

      Whitepapers & Reports

      In-depth technical analyses

      Guide & Explainers

      Educational content for all audiences

      FAQs

      Answers to common questions

      Case Studies

      Real-world clinical impact stories

      Expert Insights

      Articles and webinars from our team

      Newsletters

      Latest developments delivered to you

      Blogs

      Latest developments delivered to you

      We’ve just launched a new product!

      Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days. 

      Explore Oncolndx® 360° Endometrium
  • Press & News

      Press & News

      Press Releases

      Official announcements and statements

      In the News

      Media coverage and mentions

      Company Updates

      Latest news and developments

      Events & Conferences

      Events, talks, and participation

      Coming Soon

  • About Us

      About Us

      Our Mission 

      Why we do, what we do

      Our Team 

      Leadership, advisors, and board

      Our Lab 

      Certifications and capabilities

      Careers 

      Join our team

      We’re hiring!

      Media & Recognition 

      Awards and press coverage

x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    Knowledge Hub

    Blogs & Insights

    Deep-dive into precision oncology, clinical AI research, and the breakthroughs shaping the future of single-cell diagnostics.

    Beyond Bulk Sequencing: The Rise of Single-Cell Multi-Omics in Precision Oncology

    Beyond Bulk Sequencing: The Rise of Single-Cell Multi Omics in Precision Oncology

    ​Tumour Heterogeneity – No Two Cancer Cells Are the Same  ​Tumors do not evolve as homogenous tissue masses, but rather as dynamic, branch-evolving ecosystems...
    Jay Nyahale
    September 4, 2026
    Read More
    The Silent Threat- Understanding Minimal Residual Disease (MRD) in Cancer 

    The Silent Threat- Understanding Minimal Residual Disease (MRD) in Cancer 

    What Happens After Cancer Treatment?  The Problem With “All Clear” There’s a moment every cancer patient waits for: the scan comes back clean, the...
    Jay Nyahale
    September 4, 2026
    Read More
    ctDNA Test in India: Reading Cancer’s Molecular Story Between Biopsies

    ctDNA Test in India: Reading Cancer’s Molecular Story Between Biopsies

    A patient finishes a line of therapy. The scans look reassuring. On paper, things are stable. And yet the oncologist is left with...
    Jay Nyahale
    September 4, 2026
    Read More
    Liquid Biopsy Test in India: A Blood Test That Follows Cancer as It Changes

    Liquid Biopsy Test in India: A Blood Test That Follows Cancer as It Changes

    “The scan is stable.”  For a patient and an oncologist, few sentences bring more relief. But a stable scan doesn’t always mean a stable cancer....
    Jay Nyahale
    September 4, 2026
    Read More
    When Cancer Stops Responding: What Is the Tumor Trying to Tell Us? 

    When Cancer Stops Responding: What Is the Tumor Trying to Tell Us? 

    The treatment was working.  The scans were improving. The tumor markers were settling. For the first time in months, there was room to breathe.  And...
    Jay Nyahale
    September 4, 2026
    Read More
    The Cancer Came Back. But This Time, We Were Ready. 

    The Cancer Came Back. But This Time, We Were Ready. 

    How knowing your risk, and watching for it at the molecular level- is changing what recurrence means for cancer patients.    There are two kinds...
    Jay Nyahale
    August 31, 2026
    Read More
    Load More Articles (+6 more)

    Stay Informed

    Stay updated with the latest in Precision oncology

    Join 12,000+ oncologists, researchers, and clinical leaders reading 1Cell.Ai insights.

      Close
      1Cell.Ai
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.